|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
|
US10322949B2
(en)
|
2012-03-15 |
2019-06-18 |
Flodesign Sonics, Inc. |
Transducer and reflector configurations for an acoustophoretic device
|
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
|
US9752113B2
(en)
|
2012-03-15 |
2017-09-05 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US10689609B2
(en)
|
2012-03-15 |
2020-06-23 |
Flodesign Sonics, Inc. |
Acoustic bioreactor processes
|
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US9745548B2
(en)
|
2012-03-15 |
2017-08-29 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US10737953B2
(en)
|
2012-04-20 |
2020-08-11 |
Flodesign Sonics, Inc. |
Acoustophoretic method for use in bioreactors
|
|
US9745569B2
(en)
|
2013-09-13 |
2017-08-29 |
Flodesign Sonics, Inc. |
System for generating high concentration factors for low cell density suspensions
|
|
WO2015105955A1
(en)
|
2014-01-08 |
2015-07-16 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
|
CN106795221B
(zh)
*
|
2014-04-03 |
2022-06-07 |
塞勒克提斯公司 |
用于癌症免疫治疗的cd33特异性嵌合抗原受体
|
|
EP3131927B8
(en)
*
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
PL3134432T3
(pl)
|
2014-04-25 |
2020-10-19 |
Bluebird Bio, Inc. |
Promotor mnd chimeryczne receptory antygenowe
|
|
HUE049514T2
(hu)
|
2014-04-25 |
2020-09-28 |
Bluebird Bio Inc |
Javított eljárások adoptív sejtterápiák kialakítására
|
|
SI3151672T1
(sl)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio, Inc. |
Izboljšani T-celični sestavki
|
|
US9744483B2
(en)
|
2014-07-02 |
2017-08-29 |
Flodesign Sonics, Inc. |
Large scale acoustic separation device
|
|
ES2878449T3
(es)
|
2014-07-24 |
2021-11-18 |
2Seventy Bio Inc |
Receptores antigénicos quiméricos de BCMA
|
|
SI3226897T1
(sl)
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
|
|
MY191537A
(en)
|
2014-12-05 |
2022-06-30 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
HRP20191873T1
(hr)
|
2014-12-12 |
2020-01-24 |
Bluebird Bio, Inc. |
Kimerni antigenski receptori
|
|
BR112017013981A2
(pt)
*
|
2015-01-26 |
2018-01-02 |
Cellectis |
receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
|
|
US10294304B2
(en)
*
|
2015-04-13 |
2019-05-21 |
Pfizer Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
PL3298033T5
(pl)
|
2015-05-18 |
2023-10-30 |
TCR2 Therapeutics Inc. |
Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
|
|
WO2017019496A1
(en)
|
2015-07-24 |
2017-02-02 |
Berenson James Richard |
Gamma secretase modulators for the treatment of immune system dysfunction
|
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
WO2018028647A1
(en)
|
2016-08-10 |
2018-02-15 |
Legend Biotech Usa Inc. |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
PL3368571T3
(pl)
*
|
2015-10-30 |
2023-05-02 |
The Regents Of The University Of California |
Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
EP3408297A2
(en)
*
|
2016-01-29 |
2018-12-05 |
Med Manor Organics, (P) Ltd |
A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
|
|
CN108778329B
(zh)
|
2016-02-17 |
2022-09-16 |
西雅图基因公司 |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
EP3420077A4
(en)
*
|
2016-02-25 |
2019-12-25 |
Agenovir Corporation |
VIRAL AND ONCOVIRAL NUCLEASE TREATMENT
|
|
CA3019650C
(en)
|
2016-04-01 |
2023-07-25 |
Kite Pharma, Inc. |
Chimeric receptors and methods of use thereof
|
|
TWI795133B
(zh)
|
2016-04-01 |
2023-03-01 |
美商凱特製藥公司 |
Ｂｃｍａ結合分子類及彼等之用途
|
|
ES2891578T3
(es)
|
2016-04-01 |
2022-01-28 |
Kite Pharma Inc |
Antígeno quimérico y receptores de células T y métodos de uso
|
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
EP3666908A1
(en)
*
|
2016-06-03 |
2020-06-17 |
Institut national de recherche pour l'agriculture, l'alimentation et l'environnement |
Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein
|
|
SG10202012157QA
(en)
*
|
2016-06-07 |
2021-01-28 |
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft |
Chimeric antigen receptor and car-t cells that bind bcma
|
|
RU2019104074A
(ru)
*
|
2016-07-15 |
2020-08-18 |
Посейда Терапьютикс, Инк. |
Химерные рецепторы антигенов и способы их применения
|
|
CA3032498A1
(en)
*
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
ES2981703T3
(es)
|
2016-09-02 |
2024-10-10 |
Lentigen Tech Inc |
Composiciones y métodos para tratar cáncer con DuoCars
|
|
WO2018067993A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
WO2018075830A1
(en)
|
2016-10-19 |
2018-04-26 |
Flodesign Sonics, Inc. |
Affinity cell extraction by acoustics
|
|
WO2018085690A1
(en)
|
2016-11-04 |
2018-05-11 |
Bluebird Bio, Inc. |
Anti-bcma car t cell compositions
|
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
|
|
WO2018106993A1
(en)
*
|
2016-12-09 |
2018-06-14 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Tlr9-binding chimeric antigen receptors
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
MX2019009552A
(es)
|
2017-02-17 |
2019-10-02 |
Hutchinson Fred Cancer Res |
Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
|
|
AU2018246377B2
(en)
*
|
2017-03-31 |
2025-01-30 |
Cellectis Sa |
Universal anti-CD22 chimeric antigen receptor engineered immune cells
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
MX2019013514A
(es)
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
MY201312A
(en)
|
2017-06-02 |
2024-02-16 |
Pfizer |
Antibodies specific for flt3 and their uses
|
|
SG10202108528QA
(en)
*
|
2017-06-02 |
2021-09-29 |
Pfizer |
Chimeric antigen receptors targeting flt3
|
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
JP7385556B2
(ja)
*
|
2017-09-01 |
2023-11-22 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用
|
|
JP2020533382A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌の組合せ治療
|
|
EP3692066A2
(en)
|
2017-09-14 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
JP2020533383A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌の組合せ治療
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
AU2018351050B2
(en)
|
2017-10-18 |
2025-09-18 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
PT3703750T
(pt)
*
|
2017-11-01 |
2025-01-17 |
Memorial Sloan Kettering Cancer Center |
Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
|
|
SG11202003501XA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
MX2020004568A
(es)
|
2017-11-06 |
2020-10-05 |
Juno Therapeutics Inc |
Combinación de una terapia celular y un inhibidor de gamma secretasa.
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
CN111787938A
(zh)
|
2017-11-15 |
2020-10-16 |
诺华股份有限公司 |
靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
|
|
EP3489259A1
(en)
*
|
2017-11-23 |
2019-05-29 |
Etablissement Français du Sang |
Anti-il-1rap-car-t cells and their use
|
|
US20200371091A1
(en)
|
2017-11-30 |
2020-11-26 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
CN119193493A
(zh)
|
2017-12-08 |
2024-12-27 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
KR102439221B1
(ko)
|
2017-12-14 |
2022-09-01 |
프로디자인 소닉스, 인크. |
음향 트랜스듀서 구동기 및 제어기
|
|
US12415844B2
(en)
|
2017-12-20 |
2025-09-16 |
Poseida Therapeutics, Inc. |
BCMA specific VCAR compositions and methods for use
|
|
US12539308B2
(en)
|
2018-01-08 |
2026-02-03 |
The Trustees Of The University Of Pennsylvania |
Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
CN111094358A
(zh)
|
2018-02-11 |
2020-05-01 |
江苏恒瑞医药股份有限公司 |
一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
WO2019195017A1
(en)
*
|
2018-04-03 |
2019-10-10 |
Promab Biotechnologies, Inc. |
Bcma-car-t cells
|
|
CN116836297A
(zh)
*
|
2018-04-12 |
2023-10-03 |
上海赛比曼生物科技有限公司 |
靶向bcma的嵌合抗原受体及其制法和应用
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
MX2020012028A
(es)
|
2018-05-11 |
2021-03-29 |
Crispr Therapeutics Ag |
Metodos y composiciones para tratar el cancer.
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
JP7599205B2
(ja)
*
|
2018-06-01 |
2024-12-13 |
アンヘレス セラピューティクス インコーポレイテッド |
細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
CN109021116B
(zh)
*
|
2018-08-16 |
2022-03-22 |
重庆精准生物技术有限公司 |
抗bcma抗原的嵌合抗原受体及其应用
|
|
CN109134665B
(zh)
*
|
2018-08-24 |
2021-06-11 |
上海先博生物科技有限公司 |
一种基于单域抗体的bcma嵌合抗原受体及应用
|
|
EP4635978A2
(en)
|
2018-08-31 |
2025-10-22 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
US20220003772A1
(en)
|
2018-10-31 |
2022-01-06 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
|
EP3873937A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
|
MA54078A
(fr)
|
2018-11-01 |
2021-09-15 |
Juno Therapeutics Inc |
Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
WO2020112796A1
(en)
*
|
2018-12-01 |
2020-06-04 |
Allogene Therapeutics, Inc. |
Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereof
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
EP3941938A1
(en)
|
2019-03-06 |
2022-01-26 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
MX2021013359A
(es)
|
2019-04-30 |
2022-01-31 |
Crispr Therapeutics Ag |
Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
|
|
EP3733707A1
(en)
|
2019-04-30 |
2020-11-04 |
Celyad S.A. |
Car t-cells targeting bcma and uses thereof
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
CA3140102A1
(en)
*
|
2019-05-30 |
2020-12-03 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
|
CN120204384A
(zh)
|
2019-08-06 |
2025-06-27 |
葛兰素史密斯克莱知识产权发展有限公司 |
生物药物组合物和相关方法
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
EP4032907A4
(en)
*
|
2019-09-20 |
2023-07-05 |
Shanghai Genbase Biotechnology Co., Ltd. |
Bcma-targeted antibody and chimeric antigen receptor
|
|
WO2021061791A1
(en)
*
|
2019-09-24 |
2021-04-01 |
The Regents Of The University Of California |
Notch receptors with zinc finger-containing transcriptional effector
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
CA3160765A1
(en)
*
|
2019-12-10 |
2021-06-17 |
Abl Bio, Inc. |
Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
|
|
CN113045657B
(zh)
*
|
2019-12-26 |
2022-06-07 |
杭州济元基因科技有限公司 |
一种人源化抗人bcma单克隆抗体及其car-t细胞
|
|
WO2021144759A1
(en)
*
|
2020-01-17 |
2021-07-22 |
Crispr Therapeutics Ag |
Genetically engineered t cells expressing bcma-specific chimeric antigen receptors and uses thereof in cancer therapy
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
EP4110376A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN112851815B
(zh)
*
|
2020-03-17 |
2023-08-08 |
西安宇繁生物科技有限责任公司 |
抗bcma抗体或其抗原结合片段及其制备方法和应用
|
|
JP2023522857A
(ja)
|
2020-04-10 |
2023-06-01 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
|
|
CA3175159A1
(en)
*
|
2020-04-14 |
2021-10-21 |
Julius-Maximilians-Universitat Wurzburg |
Combination therapy of atra or other retinoids with immunotherapeutic agents binding to bcma
|
|
US20230165872A1
(en)
|
2020-04-28 |
2023-06-01 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
CN113637073B
(zh)
*
|
2020-05-11 |
2024-04-12 |
上海赛比曼生物科技有限公司 |
Bcma抗体及其制备和应用
|
|
JP2023529211A
(ja)
|
2020-06-11 |
2023-07-07 |
ノバルティス アーゲー |
Ｚｂｔｂ３２阻害剤及びその使用
|
|
KR20230025005A
(ko)
|
2020-06-17 |
2023-02-21 |
얀센 바이오테크 인코포레이티드 |
만능 줄기세포의 제조를 위한 재료 및 방법
|
|
JP7846667B2
(ja)
|
2020-07-16 |
2026-04-15 |
レジェンド バイオテック アイルランド リミテッド |
Ｃｄ２０結合分子及びその使用
|
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|
|
EP4210832A1
(en)
*
|
2020-09-14 |
2023-07-19 |
Vor Biopharma, Inc. |
Chimeric antigen receptors for treatment of cancer
|
|
CN112062864A
(zh)
*
|
2020-09-18 |
2020-12-11 |
樊克兴 |
靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
JP2024517413A
(ja)
|
2021-04-16 |
2024-04-22 |
セルジーン コーポレーション |
以前に幹細胞移植を受けた患者におけるｔ細胞療法
|
|
CN118201618A
(zh)
|
2021-04-16 |
2024-06-14 |
细胞基因公司 |
与bcma定向t细胞疗法的组合疗法
|
|
WO2022229853A1
(en)
|
2021-04-27 |
2022-11-03 |
Novartis Ag |
Viral vector production system
|
|
JP2024517863A
(ja)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞を刺激し、形質導入する方法
|
|
CN117396513A
(zh)
|
2021-05-28 |
2024-01-12 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的联合疗法
|
|
WO2022266075A1
(en)
|
2021-06-14 |
2022-12-22 |
Caribou Biosciences, Inc. |
Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
|
|
US20230174651A1
(en)
|
2021-06-23 |
2023-06-08 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
|
TW202323822A
(zh)
|
2021-08-03 |
2023-06-16 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
生藥組合物及穩定同位素標記肽之圖譜定位方法
|
|
EP4388000A1
(en)
|
2021-08-20 |
2024-06-26 |
Novartis AG |
Methods of making chimeric antigen receptor?expressing cells
|
|
CA3233953A1
(en)
|
2021-10-05 |
2023-04-13 |
Matthew Bruce |
Combination therapies for treating cancer
|
|
KR20240112994A
(ko)
|
2021-11-03 |
2024-07-19 |
셀진 코포레이션 |
골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
|
|
US20260053939A1
(en)
|
2022-01-25 |
2026-02-26 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy for Cancer
|
|
KR20240137075A
(ko)
|
2022-01-28 |
2024-09-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 조성물의 제조 방법
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
US20250295771A1
(en)
|
2022-05-11 |
2025-09-25 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
WO2024018426A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
|
JP2025525937A
(ja)
|
2022-08-05 |
2025-08-07 |
ジュノー セラピューティクス インコーポレイテッド |
Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
CN120303298A
(zh)
|
2022-12-05 |
2025-07-11 |
葛兰素史密斯克莱知识产权发展有限公司 |
使用b细胞成熟抗原拮抗剂的治疗方法
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
JP2026504491A
(ja)
|
2023-02-03 |
2026-02-05 |
ツェー３エス２ ゲーエムベーハー |
操作された免疫細胞の非ウイルス的製造のための方法
|
|
WO2024168192A1
(en)
|
2023-02-10 |
2024-08-15 |
Celgene Corporation |
Assessment of bcma in biological samples
|
|
AU2024239150A1
(en)
|
2023-03-21 |
2025-10-02 |
Biograph 55, Inc. |
Cd19/cd38 multispecific antibodies
|
|
KR20250131823A
(ko)
|
2023-03-31 |
2025-09-03 |
아벨제타 인크. |
Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025231185A1
(en)
|
2024-05-01 |
2025-11-06 |
Legend Biotech Ireland Limited |
Viral glycoprotein variants and uses thereof
|
|
WO2026072709A1
(en)
|
2024-09-25 |
2026-04-02 |
Orna Therapeutics, Inc. |
Chimeric antigen receptors targeting bcma
|